Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaPhilipp B. Staber, Claire Dearden, Marco Herling et al.|Blood|2019Cited by 161
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Christoph Kornauth et al.|Blood|2021Cited by 37
High <i>PDL1/PDL2</i> gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Fabrice Jardin, Philippe Ruminy et al.|Blood Advances|2023Cited by 17
Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACEVincent Camus, Fabrice Jardin, Mathieu Viennot et al.|Blood Advances|2024Cited by 1
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell LymphomaJuliette Pénichoux, Vincent Camus, Pierre Decazes et al.|Hematological Oncology|2025Cited by 1